Search

Mirati Therapeutics Inc

Gesloten

SectorGezondheidszorg

0

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

-0.05% downside

Nieuwssentiment

By Acuity

17%

83%

21 / 339 Rangschikking in Healthcare

Mirati Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 sep 2026, 00:05 UTC

News

Illumina Inc will join the S&P 500 on September 21, 2026. Shares are advancing in after-market hours following the announcement.

5 sep 2026, 00:05 UTC

News

Ionis Pharmaceuticals shares are lower in after-market hours following Novartis' announcement that the pelacarsen Phase 3 study did not meet its primary endpoint.

5 sep 2026, 00:01 UTC

News

Royalty Pharma PLC shares fell in after-market hours following the failed Phase 3 trial of pelacarsen, impacting its funding agreement with Ionis.

5 sep 2026, 00:01 UTC

Social Media
News

NIO shares are higher in after-market hours following a 69.1% revenue increase to approximately $4.74 billion and improved vehicle deliveries.

5 sep 2026, 00:01 UTC

News

Bloom Energy Corp will join the S&P 500 on September 21, 2026, boosting investor visibility. Shares are trading higher in after-market hours.

5 sep 2026, 00:01 UTC

News

Shares lower in after-market trading; Roth Capital targets $48.00.

5 sep 2026, 00:00 UTC

News

Campbell's Co shares increased in after-market trading following workforce cuts and price hikes aimed at improving profitability.

5 sep 2026, 00:00 UTC

News

DocuSign Inc reported stronger-than-expected second-quarter results but is trading lower in after-market hours, reflecting valuation concerns amid rising Treasury yields.

4 sep 2026, 23:40 UTC

News

DocuSign Inc. reported strong second-quarter results and raised guidance, yet shares are trading lower in after-market hours amid valuation concerns and economic context.

4 sep 2026, 23:35 UTC

News

AAP shares lower in after-market hours on analyst rating updates.

4 sep 2026, 23:27 UTC

News

Photronics Inc shares traded lower in after-market hours amid a securities class action lawsuit alleging fraud related to its product pipeline and demand stability.

4 sep 2026, 23:20 UTC

News

Monster Beverage appoints Matthew S. Burroughs as Chief Accounting Officer and Deputy CFO, with shares rising in after-market trading.

4 sep 2026, 23:10 UTC

News

Northrop Grumman was awarded a $508.49 million contract for flight test support by the U.S. Department of Defense, shares trading higher in after-market hours.

4 sep 2026, 23:05 UTC

News

Pomerantz LLP filed a class action lawsuit against Replimune Group Inc for alleged securities fraud, contributing to a decline in shares during after-market hours.

4 sep 2026, 23:02 UTC

News

Illumina Inc will join the S&P 500 index effective September 21, 2026, following an announcement by Dow Jones Indices. Shares are trading higher after the news.

4 sep 2026, 23:02 UTC

Social Media
News

Star Bulk Carriers announced a parallel listing on Euronext Athens and an equity offering. Shares are lower in after-market hours following the news.

4 sep 2026, 23:02 UTC

News

Ionis Pharmaceuticals shares declined in after-market trading following Novartis' announcement of the failed pelacarsen Phase 3 study to reduce cardiovascular events.

4 sep 2026, 23:00 UTC

News

Bloom Energy shares are higher in after-market trading following its inclusion in the S&P 500, effective September 21, 2026.

4 sep 2026, 23:00 UTC

News

FirstEnergy shares rise in after-market trading following Potomac Edison's $52.8 million rate adjustment proposal to enhance electric system reliability in Maryland.

4 sep 2026, 23:00 UTC

News

Campbell's Co announced a restructuring plan, cutting 13% of salaried jobs and closing two plants. Shares are trading higher in after-market hours.

4 sep 2026, 22:51 UTC

Correlated Moves
News

Shares rose in after-market trading amid strength in oil sector.

4 sep 2026, 20:08 UTC

News

Planet Fitness Inc. is facing a securities class action lawsuit alleging misleading statements on customer growth, contributing to a decline in its stock during Friday's session.

4 sep 2026, 20:08 UTC

News
Correlated Moves

Marten Transport Ltd shares are higher, supported by a broader transportation sector rally and an amended credit facility increasing the letters-of-credit sublimit to $50 million.

4 sep 2026, 20:08 UTC

News

Jefferies Financial Group's shares are higher as it maintains "buy" ratings and raises price targets for several banks, including Barclays and Lloyds.

4 sep 2026, 20:08 UTC

News

El Pollo Loco Holdings to participate in two investor conferences this month. Shares are trading higher, reflecting positive sentiment despite earlier session pullback.

4 sep 2026, 20:08 UTC

News

Intuitive Surgical shares declined to $365.21, marking a four-week low. Ongoing market challenges contributed to the stock's downward movement during the session.

4 sep 2026, 20:08 UTC

News
Social Media
Macro Event

McDonald's shares hit a 52-week low amid ongoing challenges, including high menu prices like $15 for an Egg McMuffin, reflecting a broader market decline.

4 sep 2026, 20:08 UTC

News

OrthoPediatrics Corp shares are lower amid broader market declines and selling pressure following a strong jobs report. A major shareholder's recent sale adds to negative sentiment.

4 sep 2026, 20:08 UTC

Social Media
Macro Event
News
Correlated Moves

Intel shares are higher as demand for CPUs surges, driven by AI workloads. Despite a price target cut to $92, investor sentiment remains positive.

4 sep 2026, 20:08 UTC

News
Correlated Moves
Social Media

Advanced Micro Devices is rising as AI demand boosts projections for its EPYC CPUs, aided by partnerships like Microsoft’s Project Zenith.

Peer Vergelijking

Prijswijziging

Mirati Therapeutics Inc Prognose

Koersdoel

By TipRanks

-0.05% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 58.67 USD  -0.05%

Hoogste 59 USD

Laagste 58 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Mirati Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

5 ratings

0

Buy

5

Hold

0

Sell

Sentiment

By Acuity

21 / 339 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

EBITDA

Operationele winst

$

Over Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.
help-icon Live chat